2022 World Conference on Lung Cancer (ePosters)-EP16.04-026. Effectiveness of Atorvastatin and SR-12813 Combination in Statin-resistant and Statin-sensitive Lung Cancer Cell Lines

EP16.04-026. Effectiveness of Atorvastatin and SR-12813 Combination in Statin-resistant and Statin-sensitive Lung Cancer Cell Lines

Back to course

Pdf Summary

The study investigated the effectiveness of combining the HMGCR inhibitor SR-12813 with the statin drug atorvastatin in lung cancer cell lines. The researchers found that SR-12813 alone inhibited cell proliferation at concentrations of 10 and 20 μM after 72 hours of treatment. When combined with atorvastatin, SR-12813 reduced the effective concentration of atorvastatin needed to inhibit cell proliferation by one-tenth. The combination also resulted in changes in cell morphology, specifically shrinkage. In statin-sensitive cancer cells, the combination of atorvastatin and SR-12813 significantly reduced cell viability compared to atorvastatin alone. Overall, the findings suggest that SR-12813 enhances the effectiveness of atorvastatin in inhibiting cancer cell proliferation.

Asset Subtitle

Tomoko Warita

Meta Tag

Speaker Tomoko Warita

Topic Tumour Biology and Biomarkers - Tumour Biology & Preclinical Studies

Keywords

HMGCR inhibitor

SR-12813

statin drug

atorvastatin

lung cancer

cell lines

cell proliferation

cell morphology

cell viability

cancer cell proliferation